Gilead Sciences, Inc. vs Oatly Group AB - ADR — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Oatly Group AB - ADR trades at $12.93 (market cap $415.98M). The key difference: Gilead Sciences, Inc. is far larger — about 404.7× Oatly Group AB - ADR's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| GILD | OTLY | |
|---|---|---|
Market Cap | $168.35B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $18.54 |
52-Week Low | $110.56 | $8.03 |
Enterprise Value | $191.42B | $920.39M |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →